Other reports using rapamycin, an mTOR inhibitor, on pancreatic cancer cells and metformin on NSCLC cells have also revealed differential effects on Akt and Erk activation, thus indicating a feedback mechanism involving mTOR and RTK signaling [56, 57]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.